AJMC urges private equity regulation

AJMC’s May 11 policy agenda argues private equity has become too large a force in U.S. health care for regulators to treat as a niche ownership issue. The paper says private equity investment in the sector has approached $1 trillion over the past decade, spanning hospitals, nursing homes, physician groups and specialty clinics, while oversight has lagged behind that expansion. (ajmc.com) The authors frame the problem in structural terms. Their argument is not just that some deals go wrong, but that private equity’s business model — rapid returns, heavy use of debt, and pressure to increase enterprise value before resale — can clash with clinical priorities in settings where staffing, access and continuity of care matter. The paper says a growing body of literature has questioned the effects of private-equity ownership on cost, quality, accessibility and equity of care. (ajmc.com) What AJMC is urging, in practical terms, falls into three buckets. First, it calls for stronger baseline oversight of consolidation. The paper says state and federal policymakers should empower antitrust authorities, strengthen existing policies, increase accountability and promote competition, with particular attention to consolidation strategies that can escape scrutiny when acquisitions are small on their own but cumulative in effect. That fits with the broader federal posture that emerged in March 2024, when the Federal Trade Commission, the Justice Department and the Department of Health and Human Services launched a joint public inquiry into private equity and other corporate control of health care. (ajmc.com) Second, the agenda pushes for health-care-specific transparency rules. AJMC’s own description of the article says the framework is aimed at increasing transparency and safeguarding clinical autonomy as private-equity investment expands. The paper also points to closer alignment between state and federal oversight and to lessons from international models that regulate financial arrangements more directly. (ajmc.com) Third, it argues for limits on extraction and for payment structures that reduce incentives to maximize short-term financial returns at the expense of care delivery. The article explicitly recommends alternative payment models and stronger patient protections against private-equity-associated clinical and nonclinical risks. In plain terms, that is an attempt to move policy beyond merger review alone and into how owned practices and facilities are run after a deal closes. (ajmc.com) The backdrop is that regulators and states have already been moving in this direction. Massachusetts lawmakers said in July 2024 that a reform bill would strengthen market oversight and impose guardrails on private-equity investments, and legal analyses published after enactment said the law signed in January 2025 expanded review requirements for health-care deals involving private equity. (malegislature.gov) The thread running through AJMC’s agenda is that private equity should be regulated as a recurring health-system issue, not handled only through case-by-case enforcement. The authors say policymakers should both curb harms and preserve potential benefits from private capital infusions, but their core recommendation is a more explicit rulebook for ownership, disclosure, incentives and patient protections. (ajmc.com) What comes next is likely to be less a single federal law than a patchwork of state legislation, antitrust scrutiny and transaction-review rules. AJMC’s paper gives lawmakers and regulators a menu: stronger antitrust tools, health-care-specific private-equity law, aligned oversight regimes, alternative payment models and tighter patient safeguards. Whether those ideas advance will depend on how aggressively states and federal agencies continue to treat private-equity ownership as a policy target rather than just a financing structure. (ajmc.com)